Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on February 19, 2021. The report details the Board of Directors' approval of modifications to the compensatory arrangements for the company's executive officers, effective January 1, 2021.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change reported is the increase in annual base salaries and the granting of equity awards to six executive officers. Specific adjustments include:
- Jack A. Khattar (CEO): Base salary increased from $836,400 to $870,000. Received a 2020 bonus of $815,500, options for 200,000 shares, and 100,000 Performance Share Units (PSUs).
- James P. Kelly (CFO): Base salary increased from $460,000 to $467,500. Received a 2020 bonus of $50,900, options for 15,000 shares, and 1,500 PSUs.
- Padmanabh P. Bhatt (CSO): Base salary increased from $391,400 to $403,100. Received a 2020 bonus of $161,600, options for 17,000 shares, and 1,500 PSUs.
- Jonathan Rubin (CMO): Base salary increased from $350,000 to $385,000. Received a 2020 bonus of $110,500, options for 25,000 shares, and 1,500 PSUs. Bonus target increased from 30% to 35% of base salary.
- Tami T. Martin (SVP, Regulatory): Base salary increased from $326,400 to $336,200. Received a 2020 bonus of $131,200, options for 17,000 shares, and 1,500 PSUs.
- Frank Mottola (SVP, Quality): Base salary increased from $316,600 to $326,100. Received a 2020 bonus of $127,200, options for 17,000 shares, and 1,500 PSUs.
Stock option grants have an exercise price of $29.61 per share, based on the closing price on February 19, 2021. Options vest annually over four years. PSUs vest based on the achievement of specified performance goals.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or discuss specific risks or contingencies. Management commentary is limited to stating that the compensation increases were the result of an annual review, are consistent with the industry peer group, and were recommended by the independent compensation consultant, Radford.
Investor Verification Checklist
- Verify the total dilution impact of the 301,000 new stock options granted to executives.
- Review the specific performance goals attached to the 105,000 PSUs to understand the conditions for vesting.
- Confirm the total cash outflow for the 2020 bonuses totaling approximately $1.2 million.
- Check the company's most recent 10-K or 10-Q for context on cash reserves relative to these new compensation obligations.